iShares MSCI Singapore ETF vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? iShares MSCI Singapore ETF trades at $31.22 (market cap $1.23B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 8.8× iShares MSCI Singapore ETF's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while iShares MSCI Singapore ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 47 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| EWS | RDY | |
|---|---|---|
Market Cap | $1.23B | $10.78B |
Volume | 3,153,173 | 2,724,343 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $15.38 |
52-Week Low | $26.71 | $11.38 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $10.68B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $31.54, down slightly by 0.03% on the day. Technical indicators are mixed, with moving averages signaling a bearish trend while oscillators suggest potential oversold conditions. The ETF recently hit a 52-week high, driven by Singapore's strong economic growth and AI momentum. Institutional interest is positive, with Amundi increasing its stake by 4.8% as of its latest 13F filing.
The outlook for EWS is cautiously optimistic, supported by Singapore's resilient economy and institutional inflows. Key risks include stretched valuations after the multi-year rally and sensitivity to regional economic shifts. Investors should weigh the strong momentum against potential pullbacks in a high-valuation environment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →